Open AccessComparing Dried Blood Spots and Plasma Concentrations for Busulfan Therapeutic Drug Monitoring in Children
Author(s) -
Ana Dilo,
Youssef Daali,
Jules Alexandre Desmeules,
Yves Chalandon,
Chakradhara Rao S. Uppugunduri,
Marc Ansari
Publication year - 2020
Publication title -
therapeutic drug monitoring
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.649
H-Index - 93
eISSN - 1536-3694
pISSN - 0163-4356
DOI - 10.1097/ftd.0000000000000673
Subject(s) - therapeutic drug monitoring , dried blood spot , busulfan , hematocrit , chromatography , phlebotomy , blood sampling , medicine , confidence interval , bland–altman plot , pharmacokinetics , whole blood , hematopoietic stem cell transplantation , chemistry , transplantation , pharmacology , nuclear medicine , limits of agreement
Busulfan (Bu) is one of the conditioning regimen components for pediatric hematopoietic stem cell transplantation. Bu therapeutic drug monitoring (TDM) is essential for a successful treatment outcome and toxicity evasion. Dried blood spot (DBS) sampling is a rapid and simple method for Bu TDM, compared with conventional plasma sampling. This study evaluated the feasibility of using the DBS method for Bu TDM. The hematocrit (Hct) and conditioning day were also examined for their impact on the DBS method's performance.